The WHO Emergency Use Listing Procedure (EUL) is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics.
Aim: Expediting the availability of these products to people affected by a public health emergency.
This also assists interested UN procurement agencies and Member States in determining the acceptability of specific products
The following criteria must be met:
The disease for which the product is intended is serious or immediately life threatening.
Existing products have not been successful in eradicating the disease or preventing outbreaks
The product is manufactured in compliance with current Good Manufacturing Practices (GMP).
The applicant undertakes to complete the development of the product and apply for WHO prequalification once the product is licensed.
What is Covaxin?
Covaxin is India’s first indigenous, whole-virion, inactivated vaccine developed by Bharat Biotech in collaboration with the Indian Medical Research Council (ICMR) and the National Institute of Virology (NIV).
It has been formulated with ‘Algel-IMDG’, which contains chemically absorbed TLR7/8 as an adjuvant onto aluminium hydroxide gel to generate the requisite type of immune responses without damaging the body.
